Best Life Sciences Companies in Petah Tikva, Israel
The 39 best Life Sciences companies in Petah Tikva, Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: PolyPid.
Our analysis of 50 Life Sciences companies
$2.2b in tracked funding; 75% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2024.
Ranked: Best Life Sciences companies in Petah Tikva
| # | Company | Last round | Disclosed funding | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Active Optical Systems Intense light and RF-based technology devices for aesthetic treatments | — | — | Unfunded | Liat Bidas CEO | — | — | — | — |
| 2 | Barimote Implantable device for eating behavior monitoring & training | — | — | Unfunded | Isaac Tavori Co-Founder & CTO | — | — | — | — |
| 3 | BeamMed Bone health assessment products | — | — | Funding Raised | — | 16 | WordPressTypeScriptPHP+25 | — | — |
| 4 | Clexio Biosciences Developer of neuromodulators or therapeutics for neurological disorders | — | — | Unfunded | Menashe Levy Co-Founder & CTO | 46 | WordPressMySQLPHP+17 | 205 patents Pharmaceutical formulations and delivery systems for esketamine treating CNS and psychiatric disorders | — |
| 5 | Crispr Stem & Therapeutics Developer of gene and cell therapy for heart diseases | — | — | Funding Raised | Dalia El-Ani Founder & CEO | — | — | — | — |
| 6 | Digma Medical Non-invasive medical device for diabetes | — | — | Funding Raised | Avia Herschkovitz Co-Founder | 14 | — | 45 patents Gastrointestinal neural ablation and submucosal modulation devices for organ function control | — |
| 7 | DirexGroup Develops medical devices primarily in the field of urology | — | — | Unfunded | — | — | WordPress Block EditorElementorWordPress+27 | — | — |
| 8 | EyeMind VR-based platform to diagnose and monitor ADHD | — | — | Deadpooled | Eran Seger Co-Founder & CEO | — | — | — | — |
Top 12 Life Sciences companies in Petah Tikva
#1
Public · Petah Tikva, Central District · founded 2000 · 37 employees$34.9Mraised▾
BrainStorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as ALS (Lou Gehrig's disease), Multiple Sclerosis (MS), and Parkinson’s disease (PD). NurOwn is BrainStorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (MSC) into neurotrophic factor (NTF)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. Its platform technology essentially converts MSCs into living drug delivery systems for NTFS. They use animal models of neurodegenerative diseases, including Parkinson's, Huntington's, ALS, MS, and peripheral nerve injury.
- Feb 2026Post IPO$1M
- Jun 2020Grant (prize money)$500K
- Apr 2020Grant (prize money)$1.5M
- Nov 2019Grant (prize money)$495.3K
#2
Public · Petah Tikva, Central District · founded 2008 · 69 employees$96.7Mraised▾
PolyPid has developed a technology platform (PLEX-Polymer-Lipid Encapsulation matriX) that enables a controlled and prolonged release of any active pharmaceutical ingredients (API). Its technology combines polymers and lipids, enabling small-and-large API entrapment in degradation and hydration protected environments, regardless of their chemical or physical characteristics. It allows the release of the API from the reservoir at pre-determined rates of up to several months, with a constant release rate. Its pipeline includes D-PLEXantibiotic drug reservoir designed to be implanted during surgery to prevent or treat surgical site infections (SSIs)), Bonypid-1000 (an antibiotic designed for bone related infections applications) and Bonypid-500 (an antibiotic eluting bone graft substitute intended to fill, augment or reconstruct periodontal or oral/maxillofacial defects while protecting from infections)
- Jun 2025Post IPO$26.7M
- Dec 2024Post IPO$14.5M
- Aug 2024Post IPO$14.2M
- Jan 2024Post IPO$35M
#3
Series B · Petah Tikva, Central District · founded 2014 · 29 employees$1Mraised▾
Biobeat offers a non-invasive body vitals monitoring wearable solution. It uses reflective Pulse Oximetry technology with their algorithm to allow for constant measurements of related body vitals. Sensor delivers a range of body vitals measurement including consciousness, saturation, pulse, temperature and perspiration. The devices are connected to a mobile app or a central monitoring system where the user's data is stored. Data is then compared against a person's normal levels to identify life-threatening situations. It also allows data sharing with doctors and caregivers. They have released their products for athletes and Hospitals. Founded by Arik Ben Ishai Director of startups in the Rocket and Space Department of the Ministry of Defense, Israel.
- Dec 2025Series B$50M
- Oct 2019Grant (prize money)$188.5K
- Jun 2016Angel$1M
#4
Series A · Petah Tikva, Central District · founded 2019$16Mraised▾
Developer of minimally invasive, bioelectronic solutions to treat spinal and synovial joint conditions. it offers minimally invasive, implantable device to treat and reverse degenerative disc disease by restoring the discs healthy fluid dynamics, cushioning and stability to the spine, revive disc cells, and accelerate tissue healing, to reduce pain and restore function.
- Sep 2024Series A$11M
- Seed$5M
#5
Series B · Petah Tikva, Central District · founded 2008 · 10 employees$72.4Mraised▾
Novaremed is focussed on developing drugs for neuropathic pain. Based on its proprietary library of small molecules identified from a biological substance with anti-inflammatory therapeutic properties, it is developing its pipeline. Its lead candidate NRD135S-E1 is a first-in-class tyrosine kinase modulator currently in phase 2 trials for the treatment of neuropathic pain via a unique and new mechanism of action.
- Jan 2021Series B$50M
- Sep 2020Series A$2.7M
- Sep 2019Series A$2.6M
- Aug 2018Series A$6.1M
#6
Series B · Petah Tikva, Central District · founded 1996 · 24 employees$33.2Mraised▾
Provider of non-invasive sensing technology for body vitals measurement. The company develops and commercializes patient monitoring solutions for non-invasive continuous measurements of haemoglobin, oxygen saturation, glucose, and other blood parameters. Utilizing its proprietary Occlusion Spectroscopy technology, it also enables the monitoring of the oxygen saturation of Hb (SpO2), low signal oximetry, SpO2, pulse rate, plethysmogram, and haemoglobin. The system is designed for use in hospitals in operating and recovery rooms and intensive care units as well as in outpatient sites and emergency services.
#7
Acquired · Petah Tikva, Central District · founded 2008 · 11 employees$26Mraised▾
MacroCure develops and commercialized T-cell therapies for wound care. Its proprietary technology CureXcell® employs activated white blood cells obtained from healthy donor blood to promote advanced wound healing. CureXcell is currently in two pivotal Phase III trials for lower extremity chronic ulcers and chronic venous leg ulcers.
- Apr 2011Series B$13M
- Sep 2009Series A$8M
- Mar 2009Series A$5M
#8
Series C · Petah Tikva, Central District · founded 2011 · 20 employees$4Mraised▾
Developer of adaptive glasses utilizing liquid crystal lenses for vision correction. The technology dynamically corrects vision impairment, functioning similarly to the human eye. This allows the wearer to focus at various distances. The adaptive sunglasses can switch to reading glasses with a swipe.
- Nov 2022Series C—
- Feb 2016Series A$4M
#9
Public · Petah Tikva, Central District · founded 1996 · 12 employees$16.3Mraised▾
Aposense has developed a proprietary platform technology, based on membrane-related cellular processes, and their recruitment to improve patient care. The Aposense Technology focuses on the electrical potential map of cell membrane, for the purposes of gene delivery, drug delivery, molecular imaging and optimization of drug pharmacokinetic profile. Based on analysis of the electrical potential map of phospholipid membranes, Aposense aims to build a proprietary Molecular Nano-Motors (MNM), capable of moving within the core of the cell membrane helping to improve drug delivery and performance.
#10
Deadpooled · Petah Tikva, Central District · founded 1996$9Mraised▾
Therapeutic products that affect the turnover of collagen
#11
Acquired · Petah Tikva, Central District · founded 1998 · 15 employees$8Mraised▾
Developer of minimally invasive visualization solutions. The company develops visualization solutions that bring natural stereoscopic sight to minimally invasive surgery. They have developed, the VSiii system, a system enabling surgeons to use a minimally invasive stereoscopic (3D) camera, for neurosurgical, ENT, arthroscopy, and laparoscopy applications.
- Oct 2009Series A$8M
#12
Public · Petah Tikva, Central District · founded 2008$5Mraised▾
Developer of cannabis-based therapeutics for multiple ailments. The company is developing topical creams and sublingual disintegrating tablets for several medical conditions, like multiple myeloma, psoriasis, fibromyalgia, PTSD (post-traumatic stress disorder), and migraines.
- May 2018Post IPO$5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Israel
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 267 Israel-affiliated papers.
- Ministry of Agriculture118
- Hebrew University of Jerusalem29
- Agricultural Research Organization25
- Tel Aviv University21
- Ben-Gurion University of the Negev19
- Mitochondrion1→5
- Gene1→18
- Plant disease resistance1→7
- Resistance (ecology)2→6
- Agriculture3→6
Where biotechnology is researched across Israel
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.